Immunization

Net monetary benefit from group B Streptococcus vaccination estimated to range from $1.1 to $17 billion

This age group is now eligible to receive the booster dose at least 2 months after they complete primary vaccination with 3 doses of the monovalent vaccine.

The table provided is a review of notable updates that occurred in February 2023 for investigational products in development.

M-M-R II, Varivax, and ProQuad are supplied in single-dose vials as lyophilized vaccine for SC or IM injection after reconstitution.

The FDA panel reviewed data from 5 clinical studies, including the phase 3 AReSVi 006 trial.

Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86 percent

Vaccine effectiveness 54 percent against medically attended outpatient acute respiratory infection associated with influenza A in patients younger than 65 years

The BLA is supported by data from a phase 3 trial which included approximately 7400 pregnant individuals.

High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions

Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions

Several changes have been made to the adult immunization schedule 2023.

Several changes have been made to the child and adolescent immunization schedule for 2023.

Highly effective against delta, moderately effective against omicron infection and hospital admission in infants

Incidence of pertussis decreased among infants younger than 2 months after maternal Tdap vaccination implementation

Vaccine effectiveness against death was lower for patients aged 80 years and older

However, the Janssen COVID-19 vaccine was associated with increased risk at 21 and 42 days postvaccination

Vaccine effectiveness with at least one dose was 64 percent against serogroup B, 82 percent against non-serogroup B disease

Committee members also weighed a proposal to streamline the dosing schedule for COVID-19 vaccines by turning them into annual shots

Additional protection against symptomatic infection provided for people who had previously received monovalent vaccine doses

Authors found low adherence to CDC recommendations for boosters, with older adults more likely to receive at least four mRNA COVID-19 vaccine doses